サンプル依頼リスト カート
  • English
  • Korean
表紙：オピオイド使用障害治療薬の世界市場-2023年～2030年
市場調査レポート
商品コード
1345456

オピオイド使用障害治療薬の世界市場-2023年～2030年

Global Opioid Use Disorder Drugs Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
オピオイド使用障害治療薬の世界市場-2023年～2030年
出版日: 2023年09月06日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

概要

世界のオピオイド使用障害（OUD）治療薬市場は、2022年に29億米ドルに達し、2023-2030年の予測期間中にCAGR 10.1％で成長し、2030年には61億米ドルに達すると予測されています。

世界のオピオイド使用障害治療薬市場は、遺伝、生活習慣、環境などの個人の特性に合わせた治療を目指す個別化医療への移行などの動向により、支配的な地位を占めると予想されます。OUDに対する最も一般的な治療法としては、薬物補助療法（MAT）と心理社会的介入を組み合わせたものがあります。

世界のオピオイド使用障害治療薬市場は近年大きく成長しており、今後も上昇傾向が続くと予測されます。不正に製造される合成オピオイドの出現など、いくつかの重要な動向の影響を受け、市場は変革期を迎えています。

さらに、オピオイド中毒患者数の増加、政府の取り組みと人々の意識の高まり、慢性疾患の有病率の上昇、製品承認の増加が、オピオイド使用障害治療薬市場規模を押し上げています。オピオイド使用障害（OUD）を治療するための研究活動が活発化していることや、確立された製薬会社の存在が、北米地域の需要促進要因の一部となっています。Mallinckrodt Pharmaceuticals、Hikma Pharmaceuticals Incなど、その他の競合企業も積極的に市場に参入しています。

ダイナミクス

FDA承認数の増加がオピオイド使用障害治療薬市場の成長を牽引

オピオイド使用障害（OUD）治療薬としてFDAが承認した薬剤の増加は、オピオイド使用障害市場の主要な促進要因です。これらの承認は治療選択肢を増やし、厳格な臨床試験を通じて有効性と安全性を高め、患者アクセスを改善します。例えば、2023年3月、ブリクサディ（ブプレノルフィン）徐放性注射剤（皮下投与）は、中等度から重度のオピオイド使用障害（OUD）治療薬として米国食品医薬品局から承認されました。

現在、ブリクサディには、経粘膜ブプレノルフィン製剤の単回投与で治療を開始した患者または既にブプレノルフィンを服用している患者を対象とした週1回注射剤と、既にブプレノルフィンを服用している患者を対象とした月1回注射剤の2つの剤形があります。このように、FDAの医薬品承認数は増加の一途をたどっており、市場は予測期間中に成長すると予想されます。

新たな償還政策の登場がオピオイド使用障害治療薬市場の成長を促進する

オピオイド使用障害治療薬市場は、オピオイド使用障害（OUD）治療薬へのアクセス向上を目的とした新たなメディケア規制の開始などの要因により、大きく成長すると見込まれます。例えば、2023年1月、メディケア＆メディケイドサービスセンター（CMS）は、救命のためのOUD治療へのアクセスがより広範になるように償還方針を改定しました。非常に効果的なOUD治療薬であるブプレノルフィンを、オピオイド治療プログラム（OTP）が遠隔医療を利用して開始できるようにするというメディケアのコミットメントは、2024年まで継続される予定です。

さらに、もし薬物乱用・精神衛生管理局が、音声のみの方法を含むテレヘルスによるOTP開始ブプレノルフィンの恒久的なガイドライン案を承認すれば、メディケアはこれらのサービスに恒久的な保険適用を与えることになります。さらにメディケアは、OUDを含む精神衛生問題を抱える患者の遠隔医療による診断、評価、治療に対して、連邦政府指定の医療センターと地方の診療所に対して、対面治療と同じ料金で払い戻しを行う。

連邦政府のデータによれば、2020年に約10億人のメディケア会員がOUDと診断され、そのうち16％未満しか投薬治療を受けていないことを考えると、この政策の更新は重要です。その結果、こうした新たな償還規制が、予測期間中のオピオイド使用障害治療薬市場の拡大に寄与すると予想されます。

オピオイド使用障害治療薬に関連する高コストが市場の成長を妨げる

オピオイド中毒の治療に使用される薬剤に関連する副作用は、オピオイド使用障害市場の成長に大きな影響を与えています。筋肉痛、嘔吐、下痢、便秘、呼吸器障害、骨・関節痛、膀胱痛、腹部けいれんなどは、すべてこれらの医薬品の一般的な副作用です。さらに、薬物有害反応が深刻な状況では、患者はうつ病やその他の精神医学的問題に苦しむ可能性があります。

さらに、これらの薬剤に関連する副作用は、米国食品医薬品局（FDA）から警告を余儀なくされ、この薬剤クラスに悪影響を与え、OUD治療薬の採用が減少する結果となっています。例えば、2022年1月、FDAはOUDおよび疼痛治療のために口腔内で溶解されるブプレノルフィン製剤に関連する歯科的懸念について警告を発していました。これらの歯科障害は、口腔感染症、虫歯、むし歯、歯の喪失を含み、重篤になる可能性があり、歯科疾患の既往歴がない患者でも観察されていることから、OUD治療薬の使用に対する懸念が高まっています。そのため、予測期間中の市場は抑制されています。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

  • 影響要因
    • 促進要因
      • FDA承認の増加
      • 新たな償還政策の出現
    • 抑制要因
      • オピオイド使用障害治療薬の高コスト
    • 機会
      • 個別化医療への需要の高まり
    • 影響分析

第5章 産業分析

  • ポーターのファイブフォース分析
  • サプライチェーン分析
  • 価格分析
  • 規制分析

第6章 COVID-19分析

第7章 薬剤タイプ別

  • アゴニスト薬
    • メタドン
    • ブプレノルフィン
    • その他
  • 拮抗薬
    • ナロキソン
    • ナルトレキソン
    • ナルメフェン
  • その他
    • クロニジン
    • ロフェキシジン
    • ベンゾジアゼピン系

第8章 投与経路別

  • 経口
  • 非経口
  • 舌下
  • 経鼻

第9章 年齢層別

  • 19～39歳
  • 40～59歳
  • 60歳以上

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ

第12章 競合情勢

  • 競合シナリオ
  • 市況/シェア分析
  • M&A分析

第13章 企業プロファイル

  • Mallinckrodt Pharmaceuticals
    • 企業概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な動向
  • Hikma Pharmaceuticals Inc
  • Collegium Pharmaceutical, Inc.
  • Braeburn, Inc.
  • Purdue Pharma L.P.
  • Curia Global Inc.
  • EMERGENT
  • Bristol-Myers Squibb, S.r.l
  • Alkermes, Inc.
  • Indivior Inc.

第14章 付録

目次
Product Code: PH6814

Overview

Global Opioid Use Disorder (OUD) Drugs Market reached US$ 2.9 billion in 2022 and is expected to reach US$ 6.1 billion by 2030 growing with a CAGR of 10.1% during the forecast period 2023-2030.

The trend such as the shift towards personalized medicine that aims tailoring treatment to an individual's unique characteristics, such as their genetics, lifestyle, and environment such The most common treatment recommendations for OUD include medication-assisted treatment (MAT) combined with psychosocial interventions is expected to dominate the global opioid use disorder drugs market.

The global opioid use disorder drugs market has grown significantly in recent years and is projected to continue on its upward trend. The market is undergoing a transformational period, influenced by several significant trends such emergence of synthetic opioids that are illicitly manufactured.

Furthermore, the growing number of opioid addiction cases, increasing number of government initiatives and awareness among the people, and rising prevalence of chronic diseases and increasing product approvals are driving up the opioid use disorder drugs market size. The growing research activities for treating opioid use disoder (OUD) and presence of establish pharmaceutical companies are some of the factors in demand from North American regions. With significant competitors like Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Inc, and others actively operating in the market.

Dynamics

The Increasing Number of FDA Approvals to Drive the Growth of the Opioid Use Disorder Drugs Market

The growing number of FDA-approved drugs for the treatment of opioid use disorder (OUD) is a major driver for the opioid use disorder market. These approvals increase therapeutic alternatives, enhance efficacy and safety through rigorous clinical trials, and improve patient access. For instance, in March 2023, Brixadi (buprenorphine) extended-release injectable for subcutaneous usage (under the skin) has been approved by the US Food and Drug Administration to treat moderate to severe opioid use disorder (OUD).

Currently, Brixadi is available in two formulations such as weekly injection for patients who started treatment with a single dose of a transmucosal buprenorphine product or who are already on buprenorphine, and a monthly injection for patients who are already on buprenorphine. Thus, as the number of FDA drug approvals continues to to increase the market is expected to grow over the forecast period.

The Emergence of New Reimbursement Policies will Drive the Opioid Use Disorder Drugs Market Growth

The opioid use disorder drugs market is expected to grow majorly owing to the factors such as the commencement of new Medicare regulations aimed at increasing access to treatment for opioid use disorder (OUD). For instance, in January 2023, the Centers for Medicare & Medicaid Services (CMS) has revised their reimbursement policies to allow for more widespread access to lifesaving OUD care. The commitment of Medicare to enabling opioid treatment programs (OTPs) to use telehealth to initiate buprenorphine, a very effective OUD drug, is scheduled to continue through 2024.

Furthermore, if the Substance Abuse and Mental Health Services Administration approves proposed guidelines for permanent OTP-initiated buprenorphine via telehealth, including audio-only methods, Medicare will give permanent coverage for these services. Additionally, Medicare will reimburse federally designated health centers and rural health clinics for telehealth-based diagnosis, evaluation, and treatment of patients with mental health problems, including OUD, at the same rates as in-person therapy.

This updation in policy is important given that about 1 Billion Medicare members were diagnosed with OUD in 2020, with less than 16% of them receiving medication for the disease, according to federal data. As a result, these new reimbursement regulations is expected to contribute to the expansion of the opioid use disorder drugs market over the forecast period.

The High Cost Associated with the Opioid Use Disorder Drugs Will Hamper the Growth of the Market

The side effects associated with the drugs used to treat opioid addiction have created a substantial impact on the opioid use disorder market growth. Muscle aches, vomiting, diarrhea, constipation, respiratory problems, bone/joint pain, bladder pain, and abdominal cramps are all common side effects of these medicines. Furthermore, in severe situations of adverse drug responses, patients may suffer from depression and other psychiatric issues.

Additionally, the side effects associated with these drugs forced a warning from the U.S. Food and Drug Administration (FDA), creating a negative impact on the drug class and resulting in lower adoption of medications for the treatment of OUD. For intance, in January 2022, FDA had given warning about dental concerns associated with buprenorphine drugs dissolved in the mouth for OUD and pain therapy. These dental disorders, which include oral infections, cavities, tooth decay, and tooth loss, can be severe and have been observed in patients with no prior history of dental problems, raising concerns about OUD drug usage. Thus, restraining the market over the forecast period.

Segment Analysis

The global opioid use disorder drugs market is segmented based on drug type, route of administration, age group, distribution channel and region.

Owing to the Better Effectiveness and its Low Potential for Drug Abuse, the Agonist Segment Accounted for Approximately 51.2% of the Opioid Use Disorder Drugs Market Share

In drug type, the agonist drugs segment is expected to dominate the market, due to proven effectiveness and its low potential for drug abuse contributing to its significance. The agonist drugs segment consists of drugs such as buprenorphine and methadone that are standard and FDA approved drugs for this disorder. Because of their effectiveness in decreasing cravings and withdrawal symptoms in patients battling with opioid addiction, these agonist drugs have long been key components of Medication-Assisted Treatment (MAT) for OUD treatment.

Also, methadone's long track record and the expanding use of buprenorphine, especially formulations like Suboxone (Buprenorphine/Naloxone combination therapy), emphasize its significance in OUD treatment. Moreover, the wide use of agonist drugs such as buprenorphine in various programs is initiating the segment growth.

For instance, in July 2023, Santa Cruz County Emergency Medical Services has launched a new program in collaboration with Monterey and San Benito counties to increase Buprenorphine distribution by emergency responders. The initiative aims to reduce opioid overdoses in the region by ensuring that this life-saving treatment is available when needed.

According to Santa Cruz County officials, buprenorphine helps reduce opiate withdrawal and cravings and is the most effective treatment for opioid use disorder when combined with methadone, reducing the risk of overdose fatalities by up to 50%. This strategic approach aligns with the overall goal of lowering fentanyl and other drug-related deaths, demonstrating agonist drugs' important role in tackling the opioid problem and thereby dominating the segment growth over the forecast period.

Geographical Penetration

North America Accounted for Approximately 39.4% of the Market Share in 2022, Owing to the Increasing Prevalence of Opioid Use Disorder

North America, particularly the U.S., dominates the global opioid use disorder drugs market due to increasing prevalence of opioid use disorder, and increasing number of investment by major organization in the region is expected to create a major impact on this market. For instance, according to StatPearls article of 2023, opioid use disorder (OUD) has affected about three Billion people in U.S. and 16 Billion people worldwide. Additionally, over 500,000 people in the U.S. are addicted to heroin. As the prevalence continues to grow, there is high requirement of effective drug therapies for this disorder.

Furthermore, the increasing investment from the top player in development of effective methods for combating this issue is major boost for the market growth. For instance, in September 2022, Bicycle Health, the leading provider of virtual opioid addiction treatment, announced a Cobalt Ventures investment to accelerate the globalization of its telehealth opioid use disorder (OUD) treatment. Bicycle Health's Series B venture capital financing has been extended, bringing the company's total funding to $88 Billion. Thus, owing to above factors the region is expected to grow over the forecast period.

Europe is expected to be positioned in second place in the market for opioid use disorder (OUD). This significant market position can be attributed to a number of key factors, including an increase in the number of new product launches in the region and an increase in the number of patients suffering from opioid addiction.

Competitive Landscape

The major global players in the opioid use disorder drugs market include: Mallinckrodt Pharmaceuticals, Hikma Pharmaceuticals Inc, Collegium Pharmaceutical, Inc., Braeburn, Inc., Purdue Pharma L.P., Curia Global Inc., EMERGENT, Bristol-Myers Squibb, S.r.l, Alkermes, Inc., Indivior Inc, and among others.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a major effect on opioid use disorder (OUD). According to a National Library of Medicine 2022 article, studies have shown that the pandemic has resulted in a spike in opioid overdose deaths, which were worse in poor, urban regions. During the pandemic, however, telemedicine played a significant role in sustaining and expanding access to OUD medication treatment. Furthermore, according to a press release from the U.S. Department of Health and Human Services 2023, telehealth services for OUD-related care have been associated with a lower risk of fatal drug overdose among Medicare beneficiaries.

The pandemic has also resulted in missed intervention touchpoints, including changes in treatment for substance use disorders and cancellation or postponement of other medical visits. The pandemic's physical and mental effects, such as despair, stress, worry, job loss, financial strain, and changing living arrangements, have all contributed to an increase in overdose deaths.

Furthermore, the pandemic has created new chances for persons who use opioids (PWUOs) to gain access to services. However, disturbances in the management of OUD patients are unavoidable. Overall, the pandemic has had a broad impact on OUD, with telemedicine playing a critical role in sustaining and expanding access to OUD medication treatment, while the pandemic has resulted in lost connections or opportunities for intervention and contributed to increased overdose deaths.

By Drug Type

  • Agonist Drugs
    • Methadone
    • Buprenorphine
    • Others
  • Antagonist Drugs
    • Naloxone
    • Naltrexone
    • Nalmefene
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Sublingual
  • Nasal

By Age Group

  • 19 to 39
  • 40 to 59
  • Age 60 and Over

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Rest of Europe
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa

Key Developments

  • On April 24, 2023, the New York State Office of Addiction Services and Supports (OASAS) and the New York State Department of Health (DOH) announced the launch of the Buprenorphine Assistance Pilot Program, which will help New Yorkers pay for the treatment of opioid use disorder (OUD) using buprenorphine. Bupe-AP will pay the cost of buprenorphine for eligible uninsured and under-insured people, leaving them with no out-of-pocket expenses.
  • On May 23, 2023, U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD).
  • On October 18, 2022, Love Pharma has signed a letter of intent to acquire transdermal drug delivery technology from Naltrexone Therapeutics in exchange for intellectual property governing the administration of an alcohol and opioid-use disorder treatment.

Why Purchase the Report?

  • To visualize the global opioid use disorder drugs market segmentation based on drug type, route of administration, age group, distribution channel and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of opioid use disorder drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping is available in excel consisting of key products of all the major players.

The global opioid use disorder drugs market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Drug Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Age Group
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The Increasing Number of FDA Approvals
      • 4.1.1.2. The Emergence of New Reimbursement Policies
    • 4.1.2. Restraints
      • 4.1.2.1. The High Cost Associated with the Opioid Use Disorder Drugs
    • 4.1.3. Opportunity
      • 4.1.3.1. Increasing Demand for Personalized Medicine
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Drug Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 7.1.2. Market Attractiveness Index, By Drug Type
  • 7.2. Agonist Drugs*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
      • 7.2.2.1. Methadone
      • 7.2.2.2. Buprenorphine
      • 7.2.2.3. Others
  • 7.3. Antagonist Drugs
    • 7.3.1. Naloxone
    • 7.3.2. Naltrexone
    • 7.3.3. Nalmefene
  • 7.4. Others
    • 7.4.1. Clonidine
    • 7.4.2. Lofexidine
    • 7.4.3. Benzodiazepines

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Oral*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Parenteral
  • 8.4. Sublingual
  • 8.5. Nasal

9. By Age Group

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 9.1.2. Market Attractiveness Index, By Age Group
  • 9.2. 19 to 39*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. 40 to 59
  • 9.4. Age 60 and over

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospitals Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Spain
      • 11.3.7.5. Italy
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. Mallinckrodt Pharmaceuticals*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. Hikma Pharmaceuticals Inc
  • 13.3. Collegium Pharmaceutical, Inc.
  • 13.4. Braeburn, Inc.
  • 13.5. Purdue Pharma L.P.
  • 13.6. Curia Global Inc.
  • 13.7. EMERGENT
  • 13.8. Bristol-Myers Squibb, S.r.l
  • 13.9. Alkermes, Inc.
  • 13.10. Indivior Inc.

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us